Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00303498 · ClinicalTrials.gov registry record · Phase 2

A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure

A Phase 2 study of Diastolic Heart Failure, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
200
Enrollment target
20
Study locations

NCT00303498 is a Phase 2 study of Diastolic Heart Failure that has completed, run by Pfizer. The registered enrollment target is 200 participants, below the 381-participant average among 7 other Diastolic Heart Failure trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00303498, a Phase 2 study of Diastolic Heart Failure, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

The aim of this study was to determine whether long-term (≥ 6 months at the target dose) blockade of ETA receptors using sitaxsentan showed functional benefit in subjects with chronic Heart Failure and an Left Ventricular Ejection Fraction ≥50%.

Conditions Studied

Diastolic Heart Failure

Interventions

  • DRUG Placebo
  • DRUG Sitexsentin sodium

Study Locations (20)

California

  • University of Southern California Medical Center - Los Angeles
  • Orange County Heart Institute and Research Center - Orange
  • Sacramento Heart & Vascular Medical Associates - Sacramento
  • University of California - San Diego

Alabama

  • University of Alabama at Birmingham - Birmingham
  • Mobile Heart Specialists, PC - Mobile
  • Preventative and Research Cardiloogy Providence Hospital - Mobile

Arizona

  • Arizona Pulmonary Specialists, LTD - Phoenix
  • Parkview Research Center - Tucson
  • Southwest Heart - Tucson

Illinois

  • The University of Chicago - Chicago
  • Methodist Medical Center - Peoria

Massachusetts

  • Massachusetts General Hospital Pulmonary and Critical Care Unit - Boston
  • Brigham and Women's Hospital - Boston

Alaska

  • Central Arkansas Veterans HCS - Little Rock

Arkansas

  • University of Arkansas for Medical Services/Cardiology Department - Little Rock

Connecticut

  • Yale University School of Medicine, Cardiovascular Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2006-03-27
Est. Completion 2008-05-01
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00303498

The ClinicalTrials.gov registry entry for NCT00303498 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 381-participant average among 7 other Diastolic Heart Failure trials with a reported enrollment target (48% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diastolic Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00303498 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00303498 about?

NCT00303498 is a clinical study titled "A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure". The aim of this study was to determine whether long-term (≥ 6 months at the target dose) blockade of ETA receptors using sitaxsentan showed functional benefit in subjects with chronic Heart Failure and an Left Ventricular Ejection Fraction ≥50%.

What is the current status of trial NCT00303498?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2006-03-27. Estimated completion is 2008-05-01.

What conditions does trial NCT00303498 study?

This clinical trial studies the following conditions: Diastolic Heart Failure.

What interventions are being tested in trial NCT00303498?

The interventions under investigation include: Placebo (DRUG), Sitexsentin sodium (DRUG).

Who is sponsoring clinical trial NCT00303498?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00303498 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diastolic Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diastolic Heart Failure

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.